Association between serum uric acid levels and atrial fibrillation risk

Cellular Physiology and Biochemistry

Volumn 38, Issue 4, 2016, Pages 1589-1595

  Zhang, Chun Hong ^a   Huang, Dang Sheng ^a   Shen, Dong ^a   Zhang, Li Wei ^a   Ma, Yong Jiang ^a   Wang, Yu Mei ^a   Sun, Hong Yan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Atrial fibrillation; Hyperuricemia; Meta analysis

Indexed keywords

URIC ACID;

ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HYPERURICEMIA; PRIORITY JOURNAL; QUALITY CONTROL; URIC ACID BLOOD LEVEL; BLOOD; COMPLICATION; FACTUAL DATABASE; META ANALYSIS; PATHOLOGY; RISK FACTOR;

ATRIAL FIBRILLATION; DATABASES, FACTUAL; HUMANS; HYPERURICEMIA; RISK FACTORS; URIC ACID;

EID: 84963594592     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000443099     Document Type: Article

References (43)

1. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the interstroke study): A case-control study. Lancet 2010; 376: 112-123
2. Jacobs V, Cutler MJ, Day JD, Bunch TJ. Atrial fibrillation and dementia. Trends Cardiovasc Med 2015; 25: 44-51
3. Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: Current status, special situations, and unmet needs. Lancet 2015; 386: 303-310
4. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the framingham heart study: A cohort study. Lancet 2015; 386: 154-162
5. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012; 379: 648-661
6. Reilly S, Liu X, Carnicer R, Rajakumar T, Sayeed R, Krasopoulos G, Verheule S, Fulga T, Schotten U, Casadei B. Evaluation of the role of MIR-31-dependent reduction in dystrophin and nnos on atrial-fibrillation-induced electrical remodelling in man. Lancet 2015; 385: S82
7. Liu Y, Geng J, Li Y, Shen J, Xiao X, Sheng L, Yang B, Cheng C, Li W. Beta3-Adrenoceptor mediates metabolic protein remodeling in a rabbit model of tachypacing-induced atrial fibrillation. Cell Physiol Biochem 2013; 32: 1631-1642
8. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: The atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol 2014; 7: 620-625
9. Rodriguez CJ, Soliman EZ, Alonso A, Swett K, Okin PM, Goff DC Jr, Heckbert SR. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: The multi-ethnic study of atherosclerosis. Ann Epidemiol 2015; 25: 71-76, 76 e71
10. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration: Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment. Lancet Diabetes Endocrinol 2014; 2: 634-647
11. Charakida M, Khan T, Johnson W, Finer N, Woodside J, Whincup PH, Sattar N, Kuh D, Hardy R, Deanfield J. Lifelong patterns of bmi and cardiovascular phenotype in individuals aged 60-64 years in the 1946 british birth cohort study: An epidemiological study. Lancet Diabetes Endocrinol 2014; 2: 648-654
12. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2015; 3: 207-215
13. Korantzopoulos P, Letsas KP, Liu T. Xanthine oxidase and uric acid in atrial fibrillation. Front Physiol 2012; 3: 150
14. Letsas KP, Korantzopoulos P, Filippatos GS, Mihas CC, Markou V, Gavrielatos G, Efremidis M, Sideris A, Kardaras F. Uric acid elevation in atrial fibrillation. Hellenic J Cardiol 2010; 51: 209-213
15. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-1799
16. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 2013; 9: 13-23
17. He XN, Li SN, Zhan JL, Xie SL, Zhang ZJ, Dong JZ, Yu RH, Long DY, Tang RB, Ma CS. Serum uric acid levels correlate with recurrence of paroxysmal atrial fibrillation after catheter ablation. Chin Med J (Engl) 2013; 126: 860-864
18. Tekin G, Tekin YK, Erbay AR, Turhan H, Yetkin E. Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure. Angiology 2013; 64: 300-303
19. Canpolat U, Aytemir K, Yorgun H, Sahiner L, Kaya EB, Cay S, Topaloglu S, Aras D, Oto A. Usefulness of serum uric acid level to predict atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2014; 16: 1731-1737
20. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Tsao HM, Chen SA. Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation-could it refine clinical risk stratification in af?. Int J Cardiol 2014; 170: 344-349
21. Nyrnes A, Toft I, Njolstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Lochen ML. Uric acid is associated with future atrial fibrillation: An 11-year follow-up of 6308 men and women-The tromso study. Europace 2014; 16: 320-326
22. Sanchis-Gomar F, Perez-Quilis C, Cervellin G, Lucia A, Lippi G. Anti-gout drugs as potential therapy for atrial fibrillation. Int J Cardiol 2014; 177: 1061-1062
23. Tang RB, Dong JZ, Yan XL, Du X, Kang JP, Wu JH, Yu RH, Long DY, Ning M, Sang CH, Jiang CX, Salim M, Bai R, Yao Y, Ma CS. Serum uric acid and risk of left atrial thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol 2014; 30: 1415-1421
24. Wan YF, Zheng YL, Niu HY, Xu CQ, He YQ, Wang Y, Chen JH, Zheng DH. Uric acid levels in obstructive sleep apnea patients with atrial fibrillation. Arch Med Res 2014; 45: 132-137
25. Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-Analyses. Eur J Epidemiol 2010; 25: 603-605
26. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ 2003; 327: 557-560
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
29. Chuang SY, Wu CC, Hsu PF, Chia-Yu Chen R, Liu WL, Hsu YY, Pan WH. Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in taiwan. Nutr Metab Cardiovasc Dis 2014; 24: 1020-1026
30. Valbusa F, Bertolini L, Bonapace S, Zenari L, Zoppini G, Arcaro G, Byrne CD, Targher G. Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. Am J Cardiol 2013; 112: 499-504
31. Chao TF, Hung CL, Chen SJ, Wang KL, Chen TJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen SA. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. Int J Cardiol 2013; 168: 4027-4032
32. Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, Ambrose M, Alonso A. Association of serum uric acid with incident atrial fibrillation (from the atherosclerosis risk in communities [aric] study). Am J Cardiol 2011; 108: 1272-1276
33. Kim SC, Liu J, Solomon DH. Risk of incident atrial fibrillation in gout: A cohort study. Ann Rheum Dis 2015; doi: 10.1136/annrheumdis-2015-208161
34. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: A systematic review and meta-Analysis. Arthritis Care Res (Hoboken) 2010; 62: 170-180
35. Abeles AM. Hyperuricemia, gout, and cardiovascular disease: An update. Curr Rheumatol Rep 2015; 17: 495
36. Faerch K, Witte DR, Tabak AG, Perreault L, Herder C, Brunner EJ, Kivimaki M, Vistisen D. Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: A post-hoc analysis of the longitudinal whitehall ii cohort study. Lancet Diabetes Endocrinol 2013; 1: 43-51
37. Wu AH, Gladden JD, Ahmed M, Ahmed A, Filippatos G. Relation of serum uric acid to cardiovascular disease. Int J Cardiol 2015
38. Hong Q, Yu S, Mei Y, Lv Y, Chen D, Wang Y, Geng W, Wu D, Cai G, Chen X. Smilacis glabrae rhizoma reduces oxidative stress caused by hyperuricemia via upregulation of catalase. Cell Physiol Biochem 2014; 34: 1675-1685
39. Zhang Y, Hong Q, Huang Z, Xue P, Lv Y, Fu B, Chen X, Wu D. Aldr enhanced endothelial injury in hyperuricemia screened using silac. Cell Physiol Biochem 2014; 33: 479-490
40. Maharani N, Ting YK, Cheng J, Hasegawa A, Kurata Y, Li P, Nakayama Y, Ninomiya H, Ikeda N, Morikawa K, Yamamoto K, Makita N, Yamashita T, Shirayoshi Y, Hisatome I. Molecular mechanisms underlying urate-induced enhancement of kv1.5 channel expression in hl-1 atrial myocytes. Circ J 2015; 79: 2659-2668
41. Kanbay M, Siriopol D, Nistor I, Elcioglu OC, Telci O, Takir M, Johnson RJ, Covic A. Effects of allopurinol on endothelial dysfunction: A meta-Analysis. Am J Nephrol 2014; 39: 348-356
42. Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: A cohort study. Am J Med 2015, doi: 10.1016/j. amjmed.2015.01.013
43. Guedes M, Esperanca A, Pereira AC, Rego C. What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol?. An evidence-based review. Rev Port Cardiol 2014; 33: 727-732